近年来,随着生物科技等前沿技术的蓬勃发展,全球范围内以细胞治疗药品和基因治疗药品为代表的药品研发、申报和批准数量持续增加,在癌症、罕见遗传疾病等疑难重症的临床治疗方面取得了突破性进展。数据显示,全球已有约2000个细胞与基因治疗(CGT)临床试验,其中中国占据了超50%的份额,在细胞治疗领域更是占全球60%以上。“自2017年传奇生物开启中国细胞与基因治疗技术的全球创新之路以来,随着工艺成本的持续...
Source Link近年来,随着生物科技等前沿技术的蓬勃发展,全球范围内以细胞治疗药品和基因治疗药品为代表的药品研发、申报和批准数量持续增加,在癌症、罕见遗传疾病等疑难重症的临床治疗方面取得了突破性进展。数据显示,全球已有约2000个细胞与基因治疗(CGT)临床试验,其中中国占据了超50%的份额,在细胞治疗领域更是占全球60%以上。“自2017年传奇生物开启中国细胞与基因治疗技术的全球创新之路以来,随着工艺成本的持续...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.